$AMED
AMEDISYS INC

2023 Q4 Form 10-Q Financial Statement

#000089626223000077 Filed on October 25, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $570.8M $556.2M
YoY Change 1.55% -0.32%
Cost Of Revenue $321.4M $311.6M
YoY Change 1.66% -3.29%
Gross Profit $249.4M $244.6M
YoY Change 1.41% 2.02%
Gross Profit Margin 43.69% 43.98%
Selling, General & Admin $199.7M $193.0M
YoY Change 3.24% 2.47%
% of Gross Profit 80.08% 78.9%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $5.847M $6.100M
YoY Change 11.8% 11.37%
% of Gross Profit 2.34% 2.49%
Operating Expenses $203.8M $197.4M
YoY Change 2.61% 1.85%
Operating Profit $45.53M $42.20M
YoY Change -3.62% 8.48%
Interest Expense -$6.022M $8.021M
YoY Change 13.32% 61.62%
% of Operating Profit -13.23% 19.01%
Other Income/Expense, Net $1.211M -$4.264M
YoY Change 193.93% 3.72%
Pretax Income $29.20M $37.95M
YoY Change -29.36% 8.98%
Income Tax $10.18M $12.33M
% Of Pretax Income 34.86% 32.5%
Net Earnings $19.32M $25.96M
YoY Change -39.08% 1.24%
Net Earnings / Revenue 3.39% 4.67%
Basic Earnings Per Share $0.80
Diluted Earnings Per Share $0.59 $0.79
COMMON SHARES
Basic Shares Outstanding 32.63M shares 32.61M shares
Diluted Shares Outstanding 32.83M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $126.5M $78.10M
YoY Change 211.91% 334.95%
Cash & Equivalents $126.5M $78.10M
Short-Term Investments
Other Short-Term Assets $30.10M $33.10M
YoY Change 14.02% -12.53%
Inventory
Prepaid Expenses $14.64M $20.53M
Receivables $313.4M $319.6M
Other Receivables $6.800M $0.00
Total Short-Term Assets $496.9M $467.2M
YoY Change 27.76% 20.18%
LONG-TERM ASSETS
Property, Plant & Equipment $41.80M $39.63M
YoY Change 161.25% 129.77%
Goodwill $1.245B $1.245B
YoY Change -3.32% -3.17%
Intangibles $102.7M $103.6M
YoY Change 1.48% -0.04%
Long-Term Investments $66.10M $65.50M
YoY Change 9.26% 6.5%
Other Assets $85.10M $84.41M
YoY Change 6.64% 4.05%
Total Long-Term Assets $1.563B $1.560B
YoY Change -1.52% -2.08%
TOTAL ASSETS
Total Short-Term Assets $496.9M $467.2M
Total Long-Term Assets $1.563B $1.560B
Total Assets $2.060B $2.027B
YoY Change 4.25% 2.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $28.24M $34.56M
YoY Change -35.44% -24.1%
Accrued Expenses $140.0M $139.1M
YoY Change 1.89% 6.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $36.30M $35.30M
YoY Change 134.19% 180.16%
Total Short-Term Liabilities $473.7M $468.1M
YoY Change 33.24% 27.48%
LONG-TERM LIABILITIES
Long-Term Debt $361.9M $366.9M
YoY Change -13.71% -17.25%
Other Long-Term Liabilities $1.400M $1.651M
YoY Change -70.83% -88.1%
Total Long-Term Liabilities $363.3M $368.6M
YoY Change -14.36% -19.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $473.7M $468.1M
Total Long-Term Liabilities $363.3M $368.6M
Total Liabilities $940.4M $933.9M
YoY Change 8.13% 2.34%
SHAREHOLDERS EQUITY
Retained Earnings $747.9M $728.6M
YoY Change -1.29% 0.36%
Common Stock $787.2M $776.9M
YoY Change 4.25% 3.46%
Preferred Stock
YoY Change
Treasury Stock (at cost) $468.6M $465.6M
YoY Change 1.61% 0.96%
Treasury Stock Shares
Shareholders Equity $1.067B $1.040B
YoY Change
Total Liabilities & Shareholders Equity $2.060B $2.027B
YoY Change 4.25% 2.28%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $19.32M $25.96M
YoY Change -39.08% 1.24%
Depreciation, Depletion And Amortization $5.847M $6.100M
YoY Change 11.8% 11.37%
Cash From Operating Activities $60.29M -$9.800M
YoY Change 47.46% -28.1%
INVESTING ACTIVITIES
Capital Expenditures $2.113M $1.200M
YoY Change 4.14% -165.04%
Acquisitions
YoY Change
Other Investing Activities $77.00K $100.0K
YoY Change -52.76% -87.68%
Cash From Investing Activities -$2.036M -$1.100M
YoY Change 9.11% 6.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -13.42M -6.300M
YoY Change -17.88% 138.55%
NET CHANGE
Cash From Operating Activities 60.29M -9.800M
Cash From Investing Activities -2.036M -1.100M
Cash From Financing Activities -13.42M -6.300M
Net Change In Cash 44.83M -17.20M
YoY Change 97.72% -0.6%
FREE CASH FLOW
Cash From Operating Activities $60.29M -$9.800M
Capital Expenditures $2.113M $1.200M
Free Cash Flow $58.17M -$11.00M
YoY Change 49.73% -6.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
556237000 usd
CY2022Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
557988000 usd
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1665594000 usd
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1661135000 usd
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3009000 usd
CY2023Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
57287000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
134534000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
2452000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
108000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
8021000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
4963000 usd
us-gaap Interest Expense
InterestExpense
23040000 usd
us-gaap Interest Expense
InterestExpense
16447000 usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1252000 usd
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
302000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
9366000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-442000 usd
CY2023Q3 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
0 usd
CY2022Q3 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
0 usd
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-106000000 usd
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
0 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1201000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
491000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5262000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1155000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4264000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4111000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-111960000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15626000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
37947000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
34820000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
10425000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
118908000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12331000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9417000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40381000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32755000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
25616000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
25403000 usd
us-gaap Profit Loss
ProfitLoss
-29956000 usd
us-gaap Profit Loss
ProfitLoss
86153000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-344000 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-239000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-887000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-739000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
25960000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
25642000 usd
us-gaap Net Income Loss
NetIncomeLoss
-29069000 usd
us-gaap Net Income Loss
NetIncomeLoss
86892000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.80
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.67
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32624000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32482000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32587000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32519000 shares
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.66
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32831000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32616000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32587000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32680000 shares
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1060757000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
848000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7243000 usd
CY2023Q3 amed Surrendered Shares
SurrenderedShares
925000 usd
CY2023Q3 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
0 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
25616000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1093518000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1038995000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
966000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
306000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3495000 usd
CY2022Q3 amed Surrendered Shares
SurrenderedShares
3187000 usd
CY2022Q3 amed Contributions Attributable To Noncontrolling Interest
ContributionsAttributableToNoncontrollingInterest
1148000 usd
CY2022Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
450000 usd
CY2022Q3 us-gaap Noncontrolling Interest Increase From Sale Of Parent Equity Interest
NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
2934000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
25403000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1069610000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1106573000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2602000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
100000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19624000 usd
amed Surrendered Shares
SurrenderedShares
4413000 usd
us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
630000 usd
amed Contributions Attributable To Noncontrolling Interest
ContributionsAttributableToNoncontrollingInterest
1232000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1614000 usd
us-gaap Profit Loss
ProfitLoss
-29956000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1093518000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
976323000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2857000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1078000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15990000 usd
amed Surrendered Shares
SurrenderedShares
7949000 usd
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
17351000 usd
amed Contributions Attributable To Noncontrolling Interest
ContributionsAttributableToNoncontrollingInterest
11000000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1425000 usd
us-gaap Noncontrolling Interest Increase From Sale Of Parent Equity Interest
NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
2934000 usd
us-gaap Profit Loss
ProfitLoss
86153000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1069610000 usd
us-gaap Profit Loss
ProfitLoss
-29956000 usd
us-gaap Profit Loss
ProfitLoss
86153000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17956000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19705000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
19624000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
15990000 usd
amed Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
25427000 usd
amed Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
34782000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-346000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-507000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-2186000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-106000000 usd
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
0 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
15417000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
19031000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
9366000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-442000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
743000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
743000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
4309000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
3798000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3009000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
32934000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
18266000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15434000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
19929000 usd
amed Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-2803000 usd
amed Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-2323000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-273000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-283000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8839000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5886000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10340000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-26790000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-3156000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
243000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-23256000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-30864000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
76877000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
92400000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
25000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
89000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
100000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
66000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3728000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4338000 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
6881000 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
848000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
637000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
15000000 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
150000 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
0 usd
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
47787000 usd
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
350000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
71952000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37103000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-92620000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1078000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2602000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2857000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4413000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
7949000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
1232000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
2100000 usd
amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
1614000 usd
amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
1425000 usd
amed Proceeds From Sale Of Noncontrolling Interest
ProceedsFromSaleOfNoncontrollingInterest
0 usd
amed Proceeds From Sale Of Noncontrolling Interest
ProceedsFromSaleOfNoncontrollingInterest
3941000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
23000000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
484000000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
465500000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
17351000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
4091000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
5714000 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
800000 usd
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-74097000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14089000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
39883000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14309000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45769000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94016000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31460000 usd
us-gaap Interest Paid Net
InterestPaidNet
19787000 usd
us-gaap Interest Paid Net
InterestPaidNet
9153000 usd
amed Cash Paid For Infinity Zpic Interest
CashPaidForInfinityZPICInterest
11544000 usd
amed Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
26059000 usd
amed Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
33187000 usd
amed Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
8462000 usd
amed Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
1074000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
25261000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
36980000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
34964000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1846000 usd
amed Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
15135000 usd
amed Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
3387000 usd
amed Lessee Finance Lease Reductions To Rou Assets Resulting From Reductions To Finance Lease Obligations
LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations
1209000 usd
amed Lessee Finance Lease Reductions To Rou Assets Resulting From Reductions To Finance Lease Obligations
LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations
564000 usd
amed Non Cash Accrued Contingent Consideration
NonCashAccruedContingentConsideration
0 usd
amed Non Cash Noncontrolling Interest Contribution
NonCashNoncontrollingInterestContribution
0 usd
amed Non Cash Noncontrolling Interest Contribution
NonCashNoncontrollingInterestContribution
8900000 usd
CY2023Q3 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
37 state
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div>
us-gaap Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods' financial statements in order to conform to the current year presentation. These reclassifications had no effect on our previously reported net income. See Note 7 - Segment Information for additional information regarding these reclassifications.</span></div>
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40500000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
15900000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
13600000 usd
CY2023Q3 amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
CY2022Q3 amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Net Service Revenue Episode Payment Rate Duration
NetServiceRevenueEpisodePaymentRateDuration
P60D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Percentage Of Total Reimbursement Of Outlier Payment
PercentageOfTotalReimbursementOfOutlierPayment
0.10
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2023Q3 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
CY2022Q3 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78100000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94000000.0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54100000 usd
amed Percentage Of Patient Receivables Outstanding
PercentageOfPatientReceivablesOutstanding
0.10
CY2023Q3 amed Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
0.65
CY2022Q4 amed Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
0.67
amed Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
0.99
CY2023Q3 amed Debt Instrument Carrying Amount Excluding Finance Leases
DebtInstrumentCarryingAmountExcludingFinanceLeases
377500000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32624000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32482000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32587000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32519000 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10000 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
38000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
50000 shares
CY2023Q3 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
197000 shares
CY2022Q3 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
96000 shares
amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
0 shares
amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
111000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32831000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32616000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32587000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32680000 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
248000 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
202000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
652000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
276000 shares
CY2023Q3 amed Minimum Percent Ownership For Controlling Interest Percent
MinimumPercentOwnershipForControllingInterestPercent
0.50
CY2023Q3 amed Maximum Percent Ownership For Equity Method Percent
MaximumPercentOwnershipForEquityMethodPercent
0.50
CY2023Q3 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
45500000 usd
CY2022Q4 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
40500000 usd
CY2023Q3 amed Maximum Percent Ownership For Cost Method Percent
MaximumPercentOwnershipForCostMethodPercent
0.20
CY2022Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
15000000 usd
CY2022Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
20000000 usd
CY2023Q3 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
20000000 usd
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3000000 usd
CY2023Q3 amed Termination Fee Payable
TerminationFeePayable
106000000 usd
CY2023Q3 amed Termination Fee Payable
TerminationFeePayable
106000000 usd
CY2023Q1 amed Disposition Closing Payment Adjustment
DispositionClosingPaymentAdjustment
1000000 usd
CY2023Q3 amed Closing Payment Adjustment Paid By Buyer
ClosingPaymentAdjustmentPaidByBuyer
100000 usd
CY2023Q1 amed Disposition Closing Payment Adjustment
DispositionClosingPaymentAdjustment
1000000 usd
amed Escrow Amount For Potential Losses
EscrowAmountForPotentialLosses
5000000 usd
CY2023Q1 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
43100000 usd
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
405000000.0 usd
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
438400000 usd
CY2023Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2800000 usd
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3500000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
402200000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
434900000 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
35300000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
15500000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
366900000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
419400000 usd
CY2023Q3 amed Total Leverage Ratio
TotalLeverageRatio
2.5
CY2023Q3 amed Consolidated Interest Coverage Ratio
ConsolidatedInterestCoverageRatio
5.5
CY2023Q1 amed Reclassification Of Operating Lease To Finance Lease
ReclassificationOfOperatingLeaseToFinanceLease
15000000 usd
amed Health Insurance Retention Limit
HealthInsuranceRetentionLimit
1300000 usd
amed Workers Compensation Insurance Retention Limit
WorkersCompensationInsuranceRetentionLimit
2000000 usd
amed Professional Liability Insurance Retention Limit
ProfessionalLiabilityInsuranceRetentionLimit
300000 usd
amed Fleet Insurance Exposure Limit
FleetInsuranceExposureLimit
400000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 segments
CY2023Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
556200000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
311600000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
198000000.0 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4400000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
514000000.0 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
42200000 usd
CY2022Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
558000000.0 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
322200000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
188400000 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5500000 usd
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3000000.0 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
38900000 usd
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1665600000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
924100000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
605500000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
13600000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1543200000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
122400000 usd
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1661100000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
943300000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
560600000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
19700000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3000000.0 usd
us-gaap Costs And Expenses
CostsAndExpenses
1526600000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
134500000 usd
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0000896262-23-000077-index-headers.html Edgar Link pending
0000896262-23-000077-index.html Edgar Link pending
0000896262-23-000077.txt Edgar Link pending
0000896262-23-000077-xbrl.zip Edgar Link pending
amed-20230930.htm Edgar Link pending
amed-20230930.xsd Edgar Link pending
amed-20230930_g1.jpg Edgar Link pending
amed-20233009xexx311.htm Edgar Link pending
amed-20233009xexx312.htm Edgar Link pending
amed-20233009xexx321.htm Edgar Link pending
amed-20233009xexx322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
amed-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
amed-20230930_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
amed-20230930_cal.xml Edgar Link unprocessable
amed-20230930_def.xml Edgar Link unprocessable
amed-20230930_lab.xml Edgar Link unprocessable